Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $4

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3.5 to $4.